Inside the research
TG Therapeutics, Inc.
TGTX Research profile · latest available data
Price overview
$57.43
▼ -0.09 (-0.2%)
| 52w hi | $59.06 |
|---|---|
| 52w lo | $26.94 |
| Vol | 1.31M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.22
| Short | +0.19 |
|---|---|
| Medium | +0.32 |
| Long | +0.09 |
computed 2026-09-27
Key fundamentals
TG Therapeutics, Inc.
Healthcare · Biotechnology
| Market cap | $8.79B |
|---|---|
| Enterprise value | $8.35B |
| Trailing P/E | 20.96x |
| Forward P/E | 19.37x |
| EV / EBITDA | 61.18x |
| P / S (ttm) | 10.99x |
| Profit margin | 55.2% |
| Return on equity | 100.3% |
| Revenue growth | +70.3% |
| Earnings growth | -70.6% |
| Debt / equity | 124.89 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.14 | |
| Sector | +0.08 | |
| Technical | +0.15 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Risk Metrics
| Beta vs SPX | 0.67 |
|---|---|
| Corr SPX | 0.21 |
| Annual vol | 52.7% |
| Annual ret | +56.1% |
| Sharpe | 1.07 |
| Max DD | -42.0% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-03 | Earnings Release, Exhibits | read |
| 2026-06-12 | Shareholder Vote | read |
| 2026-06-03 | Other Material Event, Exhibits | read |
| 2026-05-27 | Other Material Event, Exhibits | read |
| 2026-05-06 | Earnings Release, Exhibits | read |
| 2026-03-20 | Material Agreement, Material Obligation… | read |
| 2026-02-26 | Earnings Release, Exhibits | read |
| 2026-01-13 | Reg FD Disclosure, Exhibits | read |
| 2025-11-03 | Earnings Release, Exhibits | read |
| 2025-08-04 | Earnings Release, Exhibits | read |
| 2025-06-13 | Shareholder Vote, Exhibits | read |
| 2025-05-05 | Earnings Release, Exhibits | read |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 9 |
| Top-5 share | 90.7% |
| HHI | 4,185 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $427.79M | 7.79M |
| Citadel Advisors | $68.16M | 1.24M |
| Fidelity / FMR LLC | $55.97M | 1.02M |
| Renaissance Technologies | $37.32M | 679.30K |
| Capital Research / Capital World | $28.74M | 523.16K |
| AQR Capital Management | $24.30M | 442.29K |
| Bridgewater Associates | $23.62M | 429.90K |
| Millennium Management | $15.47M | 281.61K |
| T. Rowe Price Group | $152.06K | 2.77M |
As of 2026-06-30
SEC Filings
The Long Run
FY 2011–2025 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $329.00M | +199.6% | |
| Operating income | $123.32M | +194.1% | |
| Net income | $23.38M | +84.5% | |
| Cash from ops | -$31.41M | — |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $57.97 | $58.69 | $56.61 | $57.43 | 1.31M |
| Sep 24 | $55.95 | $57.55 | $55.09 | $57.52 | 1.14M |
| Sep 23 | $58.11 | $58.25 | $54.78 | $56.00 | 2.12M |
| Sep 22 | $57.41 | $58.62 | $56.56 | $58.11 | 2.08M |
| Sep 21 | $57.23 | $58.92 | $56.00 | $57.16 | 2.14M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →